Acute myeloid leukemia in the elderly: Current therapeutic results and perspectives for clinical research

Reviews on Recent Clinical Trials

Volumn 2, Issue 1, 2007, Pages 33-41

  Ferrara, Felicetto ^a,b   Pinto, Antonio ^c  

^a CARDARELLI HOSPITAL   (Italy)

^b INT Fondazione Pascale ^*  (Italy)

^c NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Acute myeloid leukemia; Elderly patients; New drugs

Indexed keywords

ALKYLATING AGENT; ANTHRACYCLINE DERIVATIVE; CD33 ANTIGEN; CLOFARABINE; CLORETAZINE; CYCLOSPORIN A; CYTARABINE; CYTOTOXIC AGENT; DAUNORUBICIN; ETOPOSIDE; FLUDARABINE; GEMTUZUMAB OZOGAMICIN; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEMOPOIETIC GROWTH FACTOR; HISTONE DEACETYLASE INHIBITOR; HYDROXYUREA; IDARUBICIN; IMATINIB; MITOXANTRONE; PROTEIN FARNESYLTRANSFERASE INHIBITOR; RETINOIC ACID; RETINOID; TIOGUANINE; TIPIFARNIB; UNCLASSIFIED DRUG; VALSPODAR; ZOSUQUIDAR;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENEIC STEM CELL TRANSPLANTATION; ANTINEOPLASTIC ACTIVITY; AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE MARROW SUPPRESSION; CANCER MORTALITY; CANCER PALLIATIVE THERAPY; CANCER REGRESSION; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; CLINICAL RESEARCH; CLINICAL TRIAL; COMORBIDITY; CONTINUOUS INFUSION; CYTOGENETICS; DISEASE FREE SURVIVAL; DRUG MEGADOSE; DRUG RESPONSE; DRUG TOLERABILITY; ELDERLY CARE; FEBRILE NEUTROPENIA; FUNCTIONAL STATUS; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; HUMAN; INFECTION; LEUKEMIA RELAPSE; LEUKOCYTOSIS; LIVER VENOOCCLUSIVE DISEASE; LOW DRUG DOSE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MYELOABLATIVE CONDITIONING; NEUTROPENIA; NONMYELOABLATIVE CONDITIONING; OVERALL SURVIVAL; PANCYTOPENIA; PATIENT SELECTION; PRIORITY JOURNAL; PROGNOSIS; PROMYELOCYTIC LEUKEMIA; RESEARCH SUBJECT; REVIEW; SURVIVAL TIME; UNSPECIFIED SIDE EFFECT;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; EVIDENCE-BASED MEDICINE; HUMANS; INCIDENCE; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 34248382171     PISSN: 15748871     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488707779318099     Document Type: Review

References (69)

1. Schiffer CA. Hematopoietic growth factors and the future of therapeutic research on acute myeloid leukemia. N Engl J Med 2003; 349: 727-29.
2. Ferrara F. Unanswered questions in acute myeloid leukaemia. Lancet Oncol; 2004; 5: 443-50.
3. Smith M, Barnett M, Bassan R, Gatta G, Tondini C, Kern W. Adult acute myeloid leukaemia. Crit Rev Oncol Hematol 2004; 50:197-222.
4. Ries LAG, Eisner MP, Kosary CL, Editors. SEER Cancer Statistics Review, 1973-1998. National Cancer Institute, Bethesda, MD, USA. 2001.
5. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer statistics, 2003. CA Cancer J Clin 2003; 53:5-26.
6. Appelbaum FR, Gundacker H, Head DR, et al. Age and acute myeloid leukemia. Blood 2006; 107: 3481-3485.
7. Pinto A, Zagonel V, Ferrara F. Acute myeloid leukemia in the elderly: biology and therapeutic strategies. Crit Rev Oncol Hematol 2001; 39: 275-87.
8. Estey EH. Prognostic factors in acute myeloid leukemia. Leukemia 2001; 15: 670-672.
9. Kern W, Haferlach T, Schoeh C, et al. Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative Group (AMLCG) 1992 Trial. Blood 2003; 101: 64-70.
10. Wheatley K, Burnett AK, Goldstone AH, et al. A simple, robust, validated and highly predictive index for the determination of riskdirected therapy in acute myeloid leukaemia derived from the MRC AML 10 trial. Br J Haematol 1999; 107: 69-79.
11. Lowemberg B. Prognostic factors in acute myeloid leukemia. Best Pract Res Clin Haematol 2001; 14: 65-75.
12. Ferrara F, Palmieri S, Mele G. Prognostic factors and therapeutic options for relapsed or refractory acute myeloid leukemia. Haematologica 2004; 89: 998-1008.
13. Estey E. General Approach to and Perspectives on Clinical Research in, Older Patients With Newly Diagnosed Acute Myeloid Leukemia. Semin Hematol 2006; 43: 89-95.
14. Goldstone AH, Burnett AK, Wheatley K, et al. Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial. Blood 2001; 98:1302-1311.
15. Grimwade D, Walker H, Harrison G, et al. MRC Adult Leukemia Working Party. The predictive value of hierarchial cytogenetic classification of older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood 2001; 98: 1312-1320.
16. Leith CP, Kopecky KJ, Godwin J, et al. Acute myeloid leukemia in the elderly: assessment ofmultidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood 1997; 89: 3323-3329.
17. Palmieri S, D'Arco AM, Celentano M, et al. An antecedent diagnosis of refractory anemia with excess blasts has no prognostic relevance in acute myeloid leukemia of older adult patients. Ann Oncol 2006; 17: 1146-1151.
18. Gupta V, Chun K, Yi QL, et al. Disease biology rather than age is the most important determinant of survival of patients > or = 60 years with acute myeloid leukemia treated with uniform intensive therapy. Cancer 2005; 103: 2082-2090.
19. Pagano L, Pulsoni A, Vignetti M, et al. Secondary acute myeloid leukaemia: results of conventional treatments. Experience of GIMEMA trials. Ann Oncol 2005; 16: 228-233.
20. Wilson CS, Davidson GS, Martin SB, et al. Gene expression profiling of adult acute myeloid leukemia identifies novel biologic clusters for risk classification and outcome prediction.Blood. 2006; 108: 685-96.
21. Grigg AP, Reynolds J, McQuillan A, et al. Prognostic features for response and survival in elderly patients with de novo acute myeloid leukemia treated with mitoxantrone and intermediate dose cytarabine. Leuk Lymphoma 2005; 46: 367-375.
22. Behringer B, Pitako JA, Kunzmann R, et al. Prognosis of older patients with acute myeloid leukemia receiving either induction or noncurative treatment: a singlecenter retrospective study. Ann Hematol 2003; 82: 381-389.
23. Ferrara F, Annunziata M, Copia C, Magrin S, Mele G, Mirto S. Therapeutic options and treatment results for patients over 75 years of age with acute myeloid leukemia. Haematologica 1998; 83: 126-131.
24. DeLima M, Ghaddar H, Pierce S, Estey E. Treatment of newly diagnosed acute myelogeneous leukaemia in patients aged 80 years and above. Br J Haematol 1996; 93: 89-95.
25. Latagliata R, Bongarzoni V, Carmosino I, et al. Acute myelogenous leukemia in elderly patients not eligible for intensive chemotherapy: the dark side of the moon. Ann Oncol 2006; 17: 281-285.
26. Hann IM, Stevens RF, Goldstone AH, et al. Randomized comparison of DAT versus ADE as induction chemotherapy in children and younger adults with acute myeloid leukemia: results of the Medical Research Council's 10th AML trial (MRC AML 10). Blood 1997; 89: 2311-2318.
27. Zittoun RA, Mandelli F, Willemze R, et al. Autologous or allogenic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. New Engl J Med 1995; 332: 217-223.
28. Cassileth PA, Harrington DP, Appelbaum FR, et al. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. New Engl J Med 1998; 339: 1649-1656.
29. Vogler WR, Velez-Garcia E, Weiner RS, et al. A phase III trial comparing idarubicin or daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group. J Clin Oncol 1992; 10: 1184-1194.
30. Reiffers J, Huguet F, Stoppa AM, et al. A prospective randomized trial of idarubicin vs daunorubicin in combination chemotherapy for acute myelogenous leukemia of the age group 55 to 75. Leukemia 1996; 10: 389-95.
31. Wiernik PH, Banks PLC, Case DC, et al. Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia. Blood 1992; 79: 313-319.
32. Lowemberg B, Suciu S, Archimbaud E, et al. Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy for manteinance of remission, and an assessment of prognostic factors in acute myeloid leukemia of the elderly: final report of the Leukemia Cooperative Group of European Organization for the Research an Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Hovon Group randomized phase III study AML-9. J Clin Oncol 1998; 16: 872-881.
33. Vogler WR, Velez-Garcia E, Weiner RS, et al. A phase III trial comparing idarubicin or daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group. J Clin Oncol 1992; 10: 1184-1194.
34. Reiffers J, Huguet F, Stoppa AM, et al. A prospective randomized trial of idarubicin vs daunorubicin in combination chemotherapy for acute myelogenous leukemia of the age group 55 to 75. Leukemia 1996; 10: 389-95.
35. Wiernik PH, Banks PLC, Case DC, et al. Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia. Blood 1992; 79: 313-319.
36. Lowemberg B, Suciu S, Archimbaud E, et al. Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy for manteinance of remission, and an assessment of prognostic factors in acute myeloid leukemia of the elderly: final report of the Leukemia Cooperative Group of European Organization for the Research an Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Hovon Group randomized phase III study AML-9. J Clin Oncol 1998; 16: 872-881.
37. De Lima M, Giralt S. Allogeneic transplantation for the elderly patient with acute myelogenous leukemia or myelodysplastic syndrome. Semin Hematol 2006; 43: 107-17.
38. Ferrara F, Palmieri S, Celentano M, et al. Feasibility of autologous peripheral blood stem cell transplantation in elderly patients with acute myeloid leukemia. Leuk Lymphoma 2006; 47: 1593-1598.
39. Ferrara F, Palmieri S, Annunziata M, et al. Continuous infusion idarubicin and oral busulfan as conditioning for patients with acute myeloid leukemia aged over 60 years undergoing autologous stem cell transplantation. Bone Marrow Transplant 2004; 34: 573-576.
40. Gross CP, Herrin J, Won Ng, Krumholz HM. Enrolling older persons in cancer trials: the effect of sociodemographic, protocol, and recruitment center characteristics. J Clin Oncol 2005; 23: 4755-4763.
41. Mengis C, Aebi S, Tobler A, Dahler W, Fey MF. Assessment of differences in patient populations selected for or excluded from participation in clinical phase III acute myelogeneous leucemia trials. J Clin Oncol 2003;21: 3933-3939.
42. Ferrara F, Mirto S, Zagonel V, Pinto A. Acute myeloid leukemia in the elderly: a critical review of therapeutic approaches and appraisal of results of therapy. Leuk Lymph 1998; 29: 375-382.
43. Ferrara F, D'Arco AM, De Simone M, et al. Fludarabine and cytarabine as continuous sequential infusion for elderly patients with acute myeloid leukaemia. Haematologica 2005; 90: 776-84.
44. Lowenberg B, Zittoun R, Kerhofs H, et al. On the value of intensive remission induction chemotherapy in elderly patients of 65+ years with acute myeloid leukemia: a randomized phase III study of the European Organization for Research and Treatment of Cancer Leukemia Group. J ClinOncol 1989; 7: 1268-1274.
45. Juliusson G, Billstrom R, Gruber A, et al. Attitude towards remission induction for elderly patients with acute myeloid leukaemia influences survival. Leykemia 2006; 20: 42-47.
46. Vey N, Coso D, Bardou VJ, et al. The Benefit of Induction Chemotherapy in Patients Age > 75 Years. Cancer 2004; 101:325-331.
47. Kantarjian H, O'Brien S, Cortes J, et al. Results of Intensive Chemotherapy in 998 Patients Age 65 Years or Older with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome. Predictive Prognostic Models for Outcome. Cancer 2006; 106: 1090-1098.
48. Ruutu T, Almqvist A, Hallman H, et al. Oral induction and consolidation of acute myeloid leukemia with etoposide, 6-thioguanine, and idarubicin (ETI) in elderly patients: a randomized comparison with 5-day TAD. Leukemia 1994; 8: 11-15.
49. Cheson BD, Jasperse DM, Simon R, Friedman MA. A critical appraisal of low-dose cytosine arabinoside in patients with acute non-lymphocytic leukemia and myelodysplastic syndromes. J Clin Oncol 1986; 4: 1854-1864.
50. Burnett AK. Milligan D, Prentice AG, Goldstone A, McMullin MF, Wheatley K. Low dose Ara-C with or without retinoid in older patients not considered fit for intensive chemotherapy: The UK NCRI AML14 trial. Blood 2004; 104: 249a (abstr).
51. Burnett AK, Mohite U. Treatment of Older Patients With Acute Myeloid Leukemia - New Agents. Semin Hematol 2006; 43: 96-106.
52. Tallman MS, Gilliland DG, Rowe JM. Drug therapy in acute myeloid leukaemia. Blood 2005; 106: 1154-1163.
53. Dombret H, Chastang C, Fenaux P, et al. A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia. New Engl J Med 1995; 332: 1678-1683.
54. Godwin JE, Kopecky KJ, Head DR, et al. A double-blind placebo-controlled trial of granulocyte colony stimulating factor in elderly patients with previously untreated acute myeloid leukemia: a Southwest oncology group study (9031). Blood 1998; 91: 3607-3615.
55. Lowenberg B, Suciu S, Archimbaud E, et al. Use of recombinant granulocyte-macrophage colony-stimulating factor durind and after remission induction chemotherapy in patients aged 61 years and older with acute myeloid leukemia (AML): final report of AML11, a phase III randomized study of the Leukemia Cooperative Group of European Organization for the Research and Treatment of Cancer (EORTC-LCG) and the Dutch Belgian Hemato-Oncology Cooperative Group (HOVON). Blood 1997; 90: 2952-2961.
56. Witz F, Dadoun A, Perrin MC, et al. A placebo-controlled study of recombinant human granulocyte macrophage colony stimulating factor administered during and after induction treatment for de novo acute myelogenous leukemia in elderly patients. Groupe Ouest Est Leucemies Aigues Myeloblastiques (GOELAM). Blood 1998; 91: 2722-2730.
57. Rowe JM, Neuberg D, Friedenberg W, et al. A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group. Blood 2004; 103: 479-485.
58. Amadori S, Suciu S, Iehn U, et al. Use of glycosylated recombinant human G-CSF (lenograstim) during and/or after induction chemotherapy in patients 61 years of age and older with acute myeloid leukemia: final results of AML-13, a randomized phase-3 study. Blood 2005; 106: 27-34.
59. Burnett AK, Hills RK, Goldstone AH, Prentice AG, Milligan D, Pallis M. Attempts to modulate chemoresistance in older patients with AML using PSC-833 - Results of LRF AML14 Trial. Blood 2003; 102: 614a (abstr).
60. Rowe JM. Is there a role for postremission therapy in older adults with acute myelogenous leukemia (AML)? Leukemia; 2005; 19: 1324-1327.
61. Burnett AK, Baccarani M, Johnson P, Yin J, Russell N. Clofarabine in previously untreated elderly (>65 yrs) AML patients with an unfavourable cytogenetic profile who are considered unfit for standard intensive chemotherapy. J Clin Oncol 2006; 18S: 6513 (abstr).
62. Faderl S, Ravandi-Kashani F, Ferrajoli A, et al. Randomized phase II study of clofarabine versus clofarabine plus low-dose cytarabine (ara-C) for patients (pts) = 60 years (yrs) with newly diagnosed acute myeloid leukemia (AML). J Clin Oncol 2005; 16S: 6627 (abstr).
63. Karp JE, Rizzieri DE, Vey N, et al. Cloretazine is an effective induction therapy in elderly patients (pts) with poor-risk de novo AML. J Clin Oncol, ASCO Annual Meeting Proceedings 2006; 18S: 6512.
64. Karp JE. Farnesyl protein transferase inhibitors as targeted therapies for hematologic malignancies. Semin Hematol 2001; 38 (Suppl 7): 16-23.
65. Lancet JE, Karp JE. Farnesyl transferase inhibitors in myeloid malignancies. Blood Rev 2003; 17: 123-129.
66. Lancet JE, Gotlib J, Gojo I, et al. Tipifarnib (ZARNESTRA) in previously untreated poor risk AML of the elderly: Updated results of a multicenter phase 2 trial. Blood 2004; 104: 249 (abstr).
67. Tsimberidou AM, Giles FJ, Esrey E, et al. The role of gemtuzumab ozogamicin in acute leukaemia therapy. Br J Haematol 2006; 132: 398-409.
68. Amadori S, Suciu S, Stasi R, et al. Gemtuzumab ozogamicin (Mylotarg) as single-agent treatment for frail patients 61 years of age and older with acute myeloid leukemia: final results of AML-15B, a phase 2 study of the European Organisation for Research and Treatment of Cancer and Gruppo Italiano Malattie Ematologiche dell'Adulto Leukemia Groups. Leukemia 2005; 19: 1768-73.
69. Amadori S, Suciu S, Willenze R, et al. Sequential administration of gemtuzumab ozogamicin and conventional chemotherapy as first line therapy in elderly patients with acute myeloid leukemia: a phase II study (AML-15) of the EORTC and GIMEMA leukemia groups. Haematologica 2004; 89: 950-6.